Science,Guidance & CareStarts Here

How it works

Activates both GIP and GLP-1 receptors, pathways involved in metabolic signaling. A dual mechanism does not by itself determine whether a medicine is suitable for a particular person.

What the evidence shows

Zepbound is FDA-approved for long-term weight reduction in specified adults and moderate-to-severe obstructive sleep apnea in adults with obesity, alongside diet and physical activity. Read the label for eligibility and indication details.

What it does not establish

These findings concern the approved product and studied populations. They do not establish the identity, quality or equivalence of research or compounded alternatives.

Safety & unanswered questions

Gastrointestinal adverse effects are common. The label includes a boxed thyroid C-cell tumor warning and severe gastrointestinal and other safety warnings. It does not recommend combining Zepbound with other tirzepatide products or GLP-1 receptor agonists.

A useful question to ask

What distinguishes an approved formulation from a research product with the same name?

Read the sources

1. Zepbound prescribing information · current label ↗ (opens in a new tab)

How it works

Designed to activate three receptor pathways: GIP, GLP-1 and glucagon. Researchers investigate how this combination affects weight and metabolism.

What the evidence shows

A randomized phase 2 obesity trial published in 2023 reported weight reduction. Gastrointestinal adverse events and increases in heart rate were observed. This is a selected study, not a claim to summarize every subsequent trial.

What it does not establish

Trial participation involves a controlled investigational product and monitoring. Results do not validate products marketed online as retatrutide or establish individual suitability.

Safety & unanswered questions

The cited trial reported gastrointestinal effects and heart-rate increases. Broader and longer-term safety questions require continuing investigation.

A useful question to ask

Is a claim based on a controlled trial, or on an unverified commercial product?

Read the sources

1. Randomized phase 2 trial · NEJM, 2023 ↗ (opens in a new tab)
2. FDA · unapproved GLP-1 products ↗ (opens in a new tab)

How it works

Laboratory studies investigate how GHK-Cu influences skin-cell behavior and extracellular-matrix components. This describes a research mechanism, not a proven whole-body rejuvenation effect.

What the evidence shows

The cited 2023 study examined fibroblasts and skin outside the body, including collagen IV responses and combinations with hyaluronic acid.

What it does not establish

This selected evidence is laboratory/ex vivo. It does not establish injectable anti-aging benefits. Evidence from a topical formulation must be assessed separately from injections and from other formulations.

Safety & unanswered questions

FDA identifies potential immunogenicity concerns for injectable GHK-Cu, including aggregation and peptide impurities, and limited human safety information.

A useful question to ask

Was the study topical, injectable, cellular, or conducted in actual patients?

Read the sources

1. Primary skin study · 2023 ↗ (opens in a new tab)
2. FDA · injectable GHK-Cu safety concerns ↗ (opens in a new tab)

How it works

Its proposed mechanism is still under investigation. Laboratory findings describe what may happen in cells or animal models, not proven effects in people.

What the evidence shows

Published evidence for this compound is limited. Check the original studies for the population, comparison group and outcomes measured.

What it does not establish

Laboratory or animal results do not establish that a compound is safe or effective in people.

Safety & unanswered questions

Safety, tolerability and interactions in people have not been established. This is not a complete safety list.

A useful question to ask

What kind of study does this claim come from?